Cibc World Markets Corp Has $2.64 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cibc World Markets Corp boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 36,676 shares of the medical equipment provider’s stock after buying an additional 5,075 shares during the quarter. Cibc World Markets Corp’s holdings in Hologic were worth $2,644,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. State Street Corp grew its holdings in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after acquiring an additional 81,057 shares during the period. FMR LLC grew its holdings in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Hologic by 0.5% in the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after buying an additional 24,358 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after buying an additional 18,774 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Hologic by 8.6% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after buying an additional 195,285 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 0.7 %

Shares of NASDAQ:HOLX opened at $61.01 on Friday. The company’s 50-day moving average price is $66.26 and its two-hundred day moving average price is $74.19. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67. The stock has a market capitalization of $13.69 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HOLX shares. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. Finally, Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.